KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced the Ministry of Health, Labor and Welfare in Japan has approved KEYTRUDA QLEX injection for subcutaneous use for all indications approved in Japan for KEYTRUDA, Merck's anti-PD-1 therapy. In Japan, KEYJECT, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. The approval of KEYJECT is based on results from the Phase 3 MK-3475A-D77 trial.
In September 2025, the FDA approved KEYTRUDA QLEX and it is now approved for adults in all the same solid tumor indications as KEYTRUDA.
In pre-market trading on NYSE, Merck shares are up 0.06 percent to $146.85.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
